A pilot randomised placebo-controlled trial of cannabidiol to reduce severe behavioural problems in children and adolescents with intellectual disability

Daryl Efron, Jeremy L Freeman, Noel Cranswick, Jonathan M Payne, Melissa Mulraney, Chidambaram Prakash, Katherine J Lee, Kaitlyn Taylor, Katrina Williams, Daryl Efron, Jeremy L Freeman, Noel Cranswick, Jonathan M Payne, Melissa Mulraney, Chidambaram Prakash, Katherine J Lee, Kaitlyn Taylor, Katrina Williams

Abstract

Aims: Severe behavioural problems (SBP) are a major contributor to morbidity in children with intellectual disability (ID). Medications used to treat SBP in ID are associated with a high risk of side effects. Cannabidiol has potential therapeutic effects in SBP. This pilot study aimed to investigate the feasibility of conducting a randomised placebo-controlled trial of cannabidiol to reduce SBP in children with ID.

Methods: This is a double-blind, placebo-controlled, two-armed, parallel-design, randomised controlled trial of cannabidiol in children aged 8-16 years with ID and SBP. Participants were randomised 1:1 to receive either 98% cannabidiol in oil (Tilray, Canada) or placebo orally for 8 weeks. The dose was up-titrated over 9 days to 20 mg/kg/day in two divided doses, with a maximum dose of 500 mg twice/day. The feasibility and acceptability of all study components were assessed.

Results: Eight children were randomised, and all completed the full study protocol. There were no serious adverse events or drop-outs. Protocol adherence for key study components was excellent: study visits 100%, medication adherence 100%, blood tests 92% and questionnaire completion 88%. Parents reported a high degree of acceptability with the study design. All parents reported they would recommend the study to other families with children with similar problems. There was an efficacy signal in favour of active drug.

Conclusions: The findings suggest that the study protocol is feasible and acceptable to patients with ID and SBP and their families.

Keywords: cannabidiol; intellectual disability; irritability; medicinal cannabis; severe behaviour problems.

© 2020 The British Pharmacological Society.

References

REFERENCES

    1. Maulik PK, Mascarenhas MN, Mathers CD, Dua T, Saxena S. Prevalence of intellectual disability: a meta-analysis of population-based studies. Res Dev Disabil. 2011;32(2):419-436.
    1. Tonge BJ, Einfeld SL. Psychopathology and intellectual disability: the Australian child to adult longitudinal study. Int Rev Res Mental Retard. 2003;26:61-91.
    1. Bhaumik S, Gangadharan S, Hiremath A, Russell PSS. Psychological treatments in intellectual disability: the challenges of building a good evidence base. Br J Psychiatry. 2011;198(6):428-430.
    1. Weiss JA, Lunsky Y, Gracey C, Canrinus M, Morris S. Emergency psychiatric services for individuals with intellectual disabilities: Caregivers' perspectives. J Appl Res Intellect Disabil. 2009;22(4):354-362.
    1. Efron D, Danchin MH, Cranswick NE, Gulenc A, Hearps S, Hiscock H. Medication prescribed by Australian paediatricians: Psychotropics predominate. J Paediatr Child Health. 2017;53(10):957-962.
    1. Sheehan R, Strydom A, Morant N, Pappa E, Hassiotis A. Psychotropic prescribing in people with intellectual disability and challenging behaviour. BMJ. 2017;358:j3896.
    1. Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis. J Clin Psychopharmacol. 2012;32(3):309-316.
    1. Einfeld SL. Systematic management approach to pharmacotherapy for people with learning disabilities. Adv Psych Treat. 2001;7(1):43-49.
    1. Melville CA, Hamilton S, Hankey CR, Miller S, Boyle S. The prevalence and determinants of obesity in adults with intellectual disabilities. Obes Rev. 2007;8(3):223-230.
    1. Trollor J, Srasuebkul P, Xu H, Howlett S. Cause of death and potentially avoidable deaths in Australian adults with intellectual disability using retrospective linked data. BMJ Open. 2017;7(2):e013489.
    1. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry. 2006;163(12):2072-2079.
    1. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456-2473.
    1. Efron D, Freeman J. Medical cannabis for paediatric developmental-behavioural and psychiatric disorders. J Paediatr Child Health. 2018;54(7):715-717.
    1. Wong SS, Wilens TE. Medical cannabinoids in children and adolescents: a systematic review. Pediatrics. 2017;140(5):e20171818.
    1. Robson P. Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf. 2011;10(5):675-685.
    1. Poleg S, Golubchik P, Offen D, Weizman A. Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2019;89:90-96.
    1. Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015;12(4):825-836.
    1. Campbell CT, Phillips MS, Manasco K. Cannabinoids in pediatrics. J Pediatr Pharmacol Therap. 2017;22(3):176-185.
    1. Földy C, Malenka RC, Südhof TC. Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling. Neuron. 2013;78(3):498-509.
    1. Jung K-M, Sepers M, Henstridge CM, et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun. 2012;3(1):1080.
    1. Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011-2020.
    1. Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378(20):1888-1897.
    1. Barchel D, Stolar O, De-Haan T, et al. Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities. Front Pharmacol. 2019;9:1521.
    1. Aran A, Cassuto H, Lubotzky A, Wattad N, Hazan E. Brief report: cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems-a retrospective feasibility study. J Autism Dev Disord. 2019;49(3):1284-1288.
    1. Schleider LB-L, Mechoulam R, Saban N, Meiri G, Novack V. Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy. Sci Rep 9, 200. 2019.
    1. Efron D, Taylor K, Freeman J, et al. Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial. BMJ Open. 2020;10(3):e034362. Published 2020 Mar 8.
    1. Wechsler D, Hsiao-pin C. WASI II: Wechsler Abbreviated Scale of Intelligence. 2nd ed. San Antonio, TX: Psychological Corporation; 2011.
    1. Sparrow S, Cicchetti DV, Saulnier CA. Vineland adaptive behavior scales, 3rd ed. (Vineland-3). San Antonio, TX: Psychological Corporation; 2016.
    1. Aman MG, Singh NN. Aberrant Behavior Checklist Manual, 2nd ed. East Aurora, NY: Slosson Educational Publications; 2017.
    1. Hansson SL, Svanströmröjvall A, Rastam M, Gillberg C, Gillberg C, Anckarsäter H. Psychiatric telephone interview with parents for screening of childhood autism-tics, attention-deficit hyperactivity disorder and other comorbidities (A-TAC): preliminary reliability and validity. Br J Psychiatry. 2005;187(3):262-267.
    1. Mårland C, Lichtenstein P, Degl’Innocenti A, et al. The Autism-Tics, ADHD and other Comorbidities inventory (A-TAC): previous and predictive validity. BMC Psychiatry. 2017;17:403.
    1. Rutter M, Bailey A, Lord C. The Social Communication Questionnaire: Manual. Torrance, CA: Western Psychological Services; 2003.
    1. Guy G, Robson P. A phase I, open label, four-way crossover study to compare the pharmacokinetic profiles of a single dose of 20 mg of a cannabis based medicine extract (CBME) administered on 3 different areas of the buccal mucosa and to investigate the pharmacokinetics of CBME per oral in healthy male and female volunteers (GWPK0112). J Cannabis Therap. 2004;3(4):79-120.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-381.
    1. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.
    1. Eldridge SM, Chan CL, Campbell MJ, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355:i5239.
    1. Bedell G. Further validation of the Child and Adolescent Scale of Participation (CASP). Dev Neurorehabil. 2009;12(5):342-351.
    1. Stevens K. Valuation of the child health utility 9D index. Pharmacoeconomics. 2012;30(8):729-747.
    1. Bruni O, Ottaviano S, Guidetti V, et al. The Sleep Disturbance Scale for Children (SDSC). Construction and validation of an instrument to evaluate sleep disturbances in childhood and adolescence. J Sleep Res. 1996;5(4):251-261.
    1. Richardson J, Iezzi A, Khan MA, Maxwell A. Validity and reliability of the Assessment of Quality of Life (AQoL)-8D multi-attribute utility instrument. Patient-Patient-Centered Outcomes Res. 2014;7(1):85-96.
    1. Hoffman L, Marquis J, Poston D, Summers JA, Turnbull A. Assessing family outcomes: psychometric evaluation of the Beach Center family quality of life scale. J Marriage Fam. 2006;68(4):1069-1083.
    1. Lovibond SH, Lovibond PF. Manual for the depression anxiety stress scales. Sydney: Psychology Foundation of Australia; 1996.
    1. Silva LM, Schalock M. Autism parenting stress index: initial psychometric evidence. J Autism Dev Disord. 2012;42(4):566-574.
    1. Kalachnik J. Standardized monitoring for psychopharmacologic medication side effects. Manual for the Monitoring of Side Effects Scale (MOSES). Columbia, SC: Center for Disability Resources, and the South Carolina Department of Disabilities and Special Needs; 2001.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться